AIM: BAG-1 is a multifunctional anti-apoptotic gene with four isoforms, and different BAG-1 isoforms have different anti-apoptotic functions. In this study, we transfected BAG-1 isoforms into the human breast cancer cell lines Hs578T (ER negative) and MCF-7 (ER positive) to study their effect on apoptosis with or without estrogens. METHODS: The constructed recombinant expression vectors carrying individual BAG-1 isoforms was used to transfect human breast cancer cell lines Hs578T (ER negative) and MCF-7 (ER positive). After stable cell lines were made, a variety of apoptosis-inducing agents, including doxorubicin, docetaxel, and 5-FU, was used to treat these cell lines with or without estrogen to test the role of BAG-1. The mechanism by which BAG-1 affected the function of Bcl-2 was exploredby using the cycloheximide chase assay. RESULTS: The BAG-1 p50 and p46 isoforms significantly enhanced the resistance to apoptosis in both cell lines according to flow cytometry analysis. BAG-1 p33 and p29 failed to protect the transfected cells from apoptosis. The cell viability assay showed that only BAG-1 p50, but not p46, p33, or p29, increased estrogen-dependent function in ER-positive cell line MCF-7. Only BAG-1 p50 dramatically increased its anti-apoptotic ability in the presence of estrogen, while estrogen has very little effect on the anti-apoptotic ability of other BAG-1 isoforms. In the detection of the expression of K-ras, Hsp70, cytochrome c, Raf-1, ER-alpha, and Bcl-2 in MCF-7 cells by Western blot, only Bcl-2 protein expression was significantly increased in MCF-7 cells transfected with BAG-1 p50 and p46, respectively. Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1 p50 and p46 transfected MCF-7 cells. CONCLUSION: Distinct isoforms of BAG-1 have different anti-apoptotic functions in breast cancer cells, and that the BAG-1 p50 isoform can potentiate the role of estrogen in ER-positive breast cancer.
AIM: BAG-1 is a multifunctional anti-apoptotic gene with four isoforms, and different BAG-1 isoforms have different anti-apoptotic functions. In this study, we transfected BAG-1 isoforms into the humanbreast cancer cell lines Hs578T (ER negative) and MCF-7 (ER positive) to study their effect on apoptosis with or without estrogens. METHODS: The constructed recombinant expression vectors carrying individual BAG-1 isoforms was used to transfect humanbreast cancer cell lines Hs578T (ER negative) and MCF-7 (ER positive). After stable cell lines were made, a variety of apoptosis-inducing agents, including doxorubicin, docetaxel, and 5-FU, was used to treat these cell lines with or without estrogen to test the role of BAG-1. The mechanism by which BAG-1 affected the function of Bcl-2 was exploredby using the cycloheximide chase assay. RESULTS: The BAG-1p50 and p46 isoforms significantly enhanced the resistance to apoptosis in both cell lines according to flow cytometry analysis. BAG-1p33 and p29 failed to protect the transfected cells from apoptosis. The cell viability assay showed that only BAG-1p50, but not p46, p33, or p29, increased estrogen-dependent function in ER-positive cell line MCF-7. Only BAG-1p50 dramatically increased its anti-apoptotic ability in the presence of estrogen, while estrogen has very little effect on the anti-apoptotic ability of other BAG-1 isoforms. In the detection of the expression of K-ras, Hsp70, cytochrome c, Raf-1, ER-alpha, and Bcl-2 in MCF-7 cells by Western blot, only Bcl-2 protein expression was significantly increased in MCF-7 cells transfected with BAG-1p50 and p46, respectively. Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1p50 and p46 transfected MCF-7 cells. CONCLUSION: Distinct isoforms of BAG-1 have different anti-apoptotic functions in breast cancer cells, and that the BAG-1p50 isoform can potentiate the role of estrogen in ER-positive breast cancer.
Authors: S Takayama; D N Bimston; S Matsuzawa; B C Freeman; C Aime-Sempe; Z Xie; R I Morimoto; J C Reed Journal: EMBO J Date: 1997-08-15 Impact factor: 11.598
Authors: Shou-Ching Tang; Jessalyn Beck; Sean Murphy; Garry Chernenko; Desmond Robb; Peter Watson; Mahmoud Khalifa Journal: Breast Cancer Res Treat Date: 2004-04 Impact factor: 4.872
Authors: Ramsey I Cutress; Paul A Townsend; Adam Sharp; Anna Maison; Lynn Wood; Ron Lee; Matthew Brimmell; Mark A Mullee; Peter W M Johnson; Gavin T Royle; Adrian C Bateman; Graham Packham Journal: Oncogene Date: 2003-08-07 Impact factor: 9.867
Authors: Eugenia Mata-Greenwood; John M Stewart; Robin H Steinhorn; William J Pearce Journal: Arterioscler Thromb Vasc Biol Date: 2013-03-14 Impact factor: 8.311
Authors: Laura Cato; Antje Neeb; Adam Sharp; Victor Buzón; Scott B Ficarro; Linxiao Yang; Claudia Muhle-Goll; Nane C Kuznik; Ruth Riisnaes; Daniel Nava Rodrigues; Olivier Armant; Victor Gourain; Guillaume Adelmant; Emmanuel A Ntim; Thomas Westerling; David Dolling; Pasquale Rescigno; Ines Figueiredo; Friedrich Fauser; Jennifer Wu; Jaice T Rottenberg; Liubov Shatkina; Claudia Ester; Burkhard Luy; Holger Puchta; Jakob Troppmair; Nicole Jung; Stefan Bräse; Uwe Strähle; Jarrod A Marto; Gerd Ulrich Nienhaus; Bissan Al-Lazikani; Xavier Salvatella; Johann S de Bono; Andrew Cb Cato; Myles Brown Journal: Elife Date: 2017-08-10 Impact factor: 8.140